Global Aphakia Market

Aphakia Comprehensive Study by Type (Primary, Secondary), Treatment (Spectacles, Contact Lenses, Intraocular Lens Implantation, Refractive Surgery), Intraocular Lens Material (PMMA, Silicon, Hydrogel), Cause of Aphakia (Cataracts, Genetics, Injuries), End User (Hospitals, Ophthalmic Clinics, Others), Symptoms (Defective vision, Erythropsia and cyanopsia) Players and Region - Global Market Outlook to 2028

Aphakia Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Aphakia is the nonappearance of the lens of the eye, due to surgical removal, a perforating wound or ulcer, or congenital anomaly. It causes a loss of accommodation, farsightedness (hyperopia), and a deep anterior chamber. Complications such as the detachment of the vitreous or retina and glaucoma. This condition is most common in adults with cataracts, but it can also affect infants and children. Aphakia is a condition in which there is an absence or dislocation of the crystalline eye lens from its normal position in the pupillary area. It occurs due to the presence of diseases such as congenital or trauma conditions or after surgery for cataract removal. This condition is most common in adults with cataracts. However, this condition can also affect infants and children.

AttributesDetails
Study Period2018-2028
Base Year2022
High Growth MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledJohnson&JohnsonServices,Inc. (United States), OphtecBV (Netherland), Novartis (Switzerland), Rayner (United Kingdom), Bohus BioTech AB (Sweden), Lifecore Biomedical (United States), Aetna Inc. (United States), The Cooper Companies Inc. (United States), Menicon (Japan) and Labtician Ophthalmics, Inc. (Canada)


This growth is primarily driven by Growing demand for treatment of the ophthalmic disease and Increased geriatric population.

Globally, a noticeable market trend is evident Major Players, such as Johnson&JohnsonServices,Inc. (United States), OphtecBV (Netherland), Novartis (Switzerland), Rayner (United Kingdom), Bohus BioTech AB (Sweden), Lifecore Biomedical (United States), Aetna Inc. (United States), The Cooper Companies Inc. (United States), Menicon (Japan) and Labtician Ophthalmics, Inc. (Canada), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The global Aphakia market is fragmented by numerous key players. The intensity of rivalry appears to be high in this market as competitors are numerous and the products are undifferentiated. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability.

Key Developments in the Market:
In February 2022, Rayner partnered with Wolffsohn Research Ltd to accelerate the development of Digitalized Health platform. This partnership strengthened its presence in aphakia market by enhancing their digital platform
In February 2019 Johnson & Johnson Vision Announces the launch of its TECNIS Eyhance IOL to treat cataracts in Europe. The TECNIS Eyhance IOL, model ICB00, is pointed to for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction.

Market Growth Drivers:
Growing demand for treatment of the ophthalmic disease and Increased geriatric population

Challenges:
Poor cosmetic appearance and Less treatment availability

Restraints:
Restrictive field of vision and Lack of a number of professionals

Opportunities:
Rapid development in the healthcare sector and rising geriatric population and technological advancement in the healthcare sector fuel

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Aphakia Market
- Analysis about New Entrants in Aphakia Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Aphakia Study Sheds Light on
— The Aphakia Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Aphakia industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Aphakia industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Primary
  • Secondary
By Treatment
  • Spectacles
  • Contact Lenses
  • Intraocular Lens Implantation
  • Refractive Surgery

By Intraocular Lens Material
  • PMMA
  • Silicon
  • Hydrogel

By Cause of Aphakia
  • Cataracts
  • Genetics
  • Injuries

By End User
  • Hospitals
  • Ophthalmic Clinics
  • Others

By Symptoms
  • Defective vision
  • Erythropsia and cyanopsia

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing demand for treatment of the ophthalmic disease
      • 3.2.2. Increased geriatric population
    • 3.3. Market Challenges
      • 3.3.1. Poor cosmetic appearance
      • 3.3.2. Less treatment availability
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aphakia, by Type, Treatment, Intraocular Lens Material, Cause of Aphakia, End User, Symptoms and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Aphakia (Value)
      • 5.2.1. Global Aphakia by: Type (Value)
        • 5.2.1.1. Primary
        • 5.2.1.2. Secondary
      • 5.2.2. Global Aphakia by: Treatment (Value)
        • 5.2.2.1. Spectacles
        • 5.2.2.2. Contact Lenses
        • 5.2.2.3. Intraocular Lens Implantation
        • 5.2.2.4. Refractive Surgery
      • 5.2.3. Global Aphakia by: Intraocular Lens Material (Value)
        • 5.2.3.1. PMMA
        • 5.2.3.2. Silicon
        • 5.2.3.3. Hydrogel
      • 5.2.4. Global Aphakia by: Cause of Aphakia (Value)
        • 5.2.4.1. Cataracts
        • 5.2.4.2. Genetics
        • 5.2.4.3. Injuries
      • 5.2.5. Global Aphakia by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Ophthalmic Clinics
        • 5.2.5.3. Others
      • 5.2.6. Global Aphakia by: Symptoms (Value)
        • 5.2.6.1. Defective vision
        • 5.2.6.2. Erythropsia and cyanopsia
      • 5.2.7. Global Aphakia Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Aphakia: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Johnson&JohnsonServices,Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. OphtecBV (Netherland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Rayner (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bohus BioTech AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Lifecore Biomedical (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aetna Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. The Cooper Companies Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Menicon (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Labtician Ophthalmics, Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Aphakia Sale, by Type, Treatment, Intraocular Lens Material, Cause of Aphakia, End User, Symptoms and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Aphakia (Value)
      • 7.2.1. Global Aphakia by: Type (Value)
        • 7.2.1.1. Primary
        • 7.2.1.2. Secondary
      • 7.2.2. Global Aphakia by: Treatment (Value)
        • 7.2.2.1. Spectacles
        • 7.2.2.2. Contact Lenses
        • 7.2.2.3. Intraocular Lens Implantation
        • 7.2.2.4. Refractive Surgery
      • 7.2.3. Global Aphakia by: Intraocular Lens Material (Value)
        • 7.2.3.1. PMMA
        • 7.2.3.2. Silicon
        • 7.2.3.3. Hydrogel
      • 7.2.4. Global Aphakia by: Cause of Aphakia (Value)
        • 7.2.4.1. Cataracts
        • 7.2.4.2. Genetics
        • 7.2.4.3. Injuries
      • 7.2.5. Global Aphakia by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Ophthalmic Clinics
        • 7.2.5.3. Others
      • 7.2.6. Global Aphakia by: Symptoms (Value)
        • 7.2.6.1. Defective vision
        • 7.2.6.2. Erythropsia and cyanopsia
      • 7.2.7. Global Aphakia Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aphakia: by Type(USD Million)
  • Table 2. Aphakia Primary , by Region USD Million (2017-2022)
  • Table 3. Aphakia Secondary , by Region USD Million (2017-2022)
  • Table 4. Aphakia: by Treatment(USD Million)
  • Table 5. Aphakia Spectacles , by Region USD Million (2017-2022)
  • Table 6. Aphakia Contact Lenses , by Region USD Million (2017-2022)
  • Table 7. Aphakia Intraocular Lens Implantation , by Region USD Million (2017-2022)
  • Table 8. Aphakia Refractive Surgery , by Region USD Million (2017-2022)
  • Table 9. Aphakia: by Intraocular Lens Material(USD Million)
  • Table 10. Aphakia PMMA , by Region USD Million (2017-2022)
  • Table 11. Aphakia Silicon , by Region USD Million (2017-2022)
  • Table 12. Aphakia Hydrogel , by Region USD Million (2017-2022)
  • Table 13. Aphakia: by Cause of Aphakia(USD Million)
  • Table 14. Aphakia Cataracts , by Region USD Million (2017-2022)
  • Table 15. Aphakia Genetics , by Region USD Million (2017-2022)
  • Table 16. Aphakia Injuries , by Region USD Million (2017-2022)
  • Table 17. Aphakia: by End User(USD Million)
  • Table 18. Aphakia Hospitals , by Region USD Million (2017-2022)
  • Table 19. Aphakia Ophthalmic Clinics , by Region USD Million (2017-2022)
  • Table 20. Aphakia Others , by Region USD Million (2017-2022)
  • Table 21. Aphakia: by Symptoms(USD Million)
  • Table 22. Aphakia Defective vision , by Region USD Million (2017-2022)
  • Table 23. Aphakia Erythropsia and cyanopsia , by Region USD Million (2017-2022)
  • Table 24. South America Aphakia, by Country USD Million (2017-2022)
  • Table 25. South America Aphakia, by Type USD Million (2017-2022)
  • Table 26. South America Aphakia, by Treatment USD Million (2017-2022)
  • Table 27. South America Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 28. South America Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 29. South America Aphakia, by End User USD Million (2017-2022)
  • Table 30. South America Aphakia, by Symptoms USD Million (2017-2022)
  • Table 31. Brazil Aphakia, by Type USD Million (2017-2022)
  • Table 32. Brazil Aphakia, by Treatment USD Million (2017-2022)
  • Table 33. Brazil Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 34. Brazil Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 35. Brazil Aphakia, by End User USD Million (2017-2022)
  • Table 36. Brazil Aphakia, by Symptoms USD Million (2017-2022)
  • Table 37. Argentina Aphakia, by Type USD Million (2017-2022)
  • Table 38. Argentina Aphakia, by Treatment USD Million (2017-2022)
  • Table 39. Argentina Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 40. Argentina Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 41. Argentina Aphakia, by End User USD Million (2017-2022)
  • Table 42. Argentina Aphakia, by Symptoms USD Million (2017-2022)
  • Table 43. Rest of South America Aphakia, by Type USD Million (2017-2022)
  • Table 44. Rest of South America Aphakia, by Treatment USD Million (2017-2022)
  • Table 45. Rest of South America Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 46. Rest of South America Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 47. Rest of South America Aphakia, by End User USD Million (2017-2022)
  • Table 48. Rest of South America Aphakia, by Symptoms USD Million (2017-2022)
  • Table 49. Asia Pacific Aphakia, by Country USD Million (2017-2022)
  • Table 50. Asia Pacific Aphakia, by Type USD Million (2017-2022)
  • Table 51. Asia Pacific Aphakia, by Treatment USD Million (2017-2022)
  • Table 52. Asia Pacific Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 53. Asia Pacific Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 54. Asia Pacific Aphakia, by End User USD Million (2017-2022)
  • Table 55. Asia Pacific Aphakia, by Symptoms USD Million (2017-2022)
  • Table 56. China Aphakia, by Type USD Million (2017-2022)
  • Table 57. China Aphakia, by Treatment USD Million (2017-2022)
  • Table 58. China Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 59. China Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 60. China Aphakia, by End User USD Million (2017-2022)
  • Table 61. China Aphakia, by Symptoms USD Million (2017-2022)
  • Table 62. Japan Aphakia, by Type USD Million (2017-2022)
  • Table 63. Japan Aphakia, by Treatment USD Million (2017-2022)
  • Table 64. Japan Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 65. Japan Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 66. Japan Aphakia, by End User USD Million (2017-2022)
  • Table 67. Japan Aphakia, by Symptoms USD Million (2017-2022)
  • Table 68. India Aphakia, by Type USD Million (2017-2022)
  • Table 69. India Aphakia, by Treatment USD Million (2017-2022)
  • Table 70. India Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 71. India Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 72. India Aphakia, by End User USD Million (2017-2022)
  • Table 73. India Aphakia, by Symptoms USD Million (2017-2022)
  • Table 74. South Korea Aphakia, by Type USD Million (2017-2022)
  • Table 75. South Korea Aphakia, by Treatment USD Million (2017-2022)
  • Table 76. South Korea Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 77. South Korea Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 78. South Korea Aphakia, by End User USD Million (2017-2022)
  • Table 79. South Korea Aphakia, by Symptoms USD Million (2017-2022)
  • Table 80. Taiwan Aphakia, by Type USD Million (2017-2022)
  • Table 81. Taiwan Aphakia, by Treatment USD Million (2017-2022)
  • Table 82. Taiwan Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 83. Taiwan Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 84. Taiwan Aphakia, by End User USD Million (2017-2022)
  • Table 85. Taiwan Aphakia, by Symptoms USD Million (2017-2022)
  • Table 86. Australia Aphakia, by Type USD Million (2017-2022)
  • Table 87. Australia Aphakia, by Treatment USD Million (2017-2022)
  • Table 88. Australia Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 89. Australia Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 90. Australia Aphakia, by End User USD Million (2017-2022)
  • Table 91. Australia Aphakia, by Symptoms USD Million (2017-2022)
  • Table 92. Rest of Asia-Pacific Aphakia, by Type USD Million (2017-2022)
  • Table 93. Rest of Asia-Pacific Aphakia, by Treatment USD Million (2017-2022)
  • Table 94. Rest of Asia-Pacific Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 95. Rest of Asia-Pacific Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 96. Rest of Asia-Pacific Aphakia, by End User USD Million (2017-2022)
  • Table 97. Rest of Asia-Pacific Aphakia, by Symptoms USD Million (2017-2022)
  • Table 98. Europe Aphakia, by Country USD Million (2017-2022)
  • Table 99. Europe Aphakia, by Type USD Million (2017-2022)
  • Table 100. Europe Aphakia, by Treatment USD Million (2017-2022)
  • Table 101. Europe Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 102. Europe Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 103. Europe Aphakia, by End User USD Million (2017-2022)
  • Table 104. Europe Aphakia, by Symptoms USD Million (2017-2022)
  • Table 105. Germany Aphakia, by Type USD Million (2017-2022)
  • Table 106. Germany Aphakia, by Treatment USD Million (2017-2022)
  • Table 107. Germany Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 108. Germany Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 109. Germany Aphakia, by End User USD Million (2017-2022)
  • Table 110. Germany Aphakia, by Symptoms USD Million (2017-2022)
  • Table 111. France Aphakia, by Type USD Million (2017-2022)
  • Table 112. France Aphakia, by Treatment USD Million (2017-2022)
  • Table 113. France Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 114. France Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 115. France Aphakia, by End User USD Million (2017-2022)
  • Table 116. France Aphakia, by Symptoms USD Million (2017-2022)
  • Table 117. Italy Aphakia, by Type USD Million (2017-2022)
  • Table 118. Italy Aphakia, by Treatment USD Million (2017-2022)
  • Table 119. Italy Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 120. Italy Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 121. Italy Aphakia, by End User USD Million (2017-2022)
  • Table 122. Italy Aphakia, by Symptoms USD Million (2017-2022)
  • Table 123. United Kingdom Aphakia, by Type USD Million (2017-2022)
  • Table 124. United Kingdom Aphakia, by Treatment USD Million (2017-2022)
  • Table 125. United Kingdom Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 126. United Kingdom Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 127. United Kingdom Aphakia, by End User USD Million (2017-2022)
  • Table 128. United Kingdom Aphakia, by Symptoms USD Million (2017-2022)
  • Table 129. Netherlands Aphakia, by Type USD Million (2017-2022)
  • Table 130. Netherlands Aphakia, by Treatment USD Million (2017-2022)
  • Table 131. Netherlands Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 132. Netherlands Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 133. Netherlands Aphakia, by End User USD Million (2017-2022)
  • Table 134. Netherlands Aphakia, by Symptoms USD Million (2017-2022)
  • Table 135. Rest of Europe Aphakia, by Type USD Million (2017-2022)
  • Table 136. Rest of Europe Aphakia, by Treatment USD Million (2017-2022)
  • Table 137. Rest of Europe Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 138. Rest of Europe Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 139. Rest of Europe Aphakia, by End User USD Million (2017-2022)
  • Table 140. Rest of Europe Aphakia, by Symptoms USD Million (2017-2022)
  • Table 141. MEA Aphakia, by Country USD Million (2017-2022)
  • Table 142. MEA Aphakia, by Type USD Million (2017-2022)
  • Table 143. MEA Aphakia, by Treatment USD Million (2017-2022)
  • Table 144. MEA Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 145. MEA Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 146. MEA Aphakia, by End User USD Million (2017-2022)
  • Table 147. MEA Aphakia, by Symptoms USD Million (2017-2022)
  • Table 148. Middle East Aphakia, by Type USD Million (2017-2022)
  • Table 149. Middle East Aphakia, by Treatment USD Million (2017-2022)
  • Table 150. Middle East Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 151. Middle East Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 152. Middle East Aphakia, by End User USD Million (2017-2022)
  • Table 153. Middle East Aphakia, by Symptoms USD Million (2017-2022)
  • Table 154. Africa Aphakia, by Type USD Million (2017-2022)
  • Table 155. Africa Aphakia, by Treatment USD Million (2017-2022)
  • Table 156. Africa Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 157. Africa Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 158. Africa Aphakia, by End User USD Million (2017-2022)
  • Table 159. Africa Aphakia, by Symptoms USD Million (2017-2022)
  • Table 160. North America Aphakia, by Country USD Million (2017-2022)
  • Table 161. North America Aphakia, by Type USD Million (2017-2022)
  • Table 162. North America Aphakia, by Treatment USD Million (2017-2022)
  • Table 163. North America Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 164. North America Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 165. North America Aphakia, by End User USD Million (2017-2022)
  • Table 166. North America Aphakia, by Symptoms USD Million (2017-2022)
  • Table 167. United States Aphakia, by Type USD Million (2017-2022)
  • Table 168. United States Aphakia, by Treatment USD Million (2017-2022)
  • Table 169. United States Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 170. United States Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 171. United States Aphakia, by End User USD Million (2017-2022)
  • Table 172. United States Aphakia, by Symptoms USD Million (2017-2022)
  • Table 173. Canada Aphakia, by Type USD Million (2017-2022)
  • Table 174. Canada Aphakia, by Treatment USD Million (2017-2022)
  • Table 175. Canada Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 176. Canada Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 177. Canada Aphakia, by End User USD Million (2017-2022)
  • Table 178. Canada Aphakia, by Symptoms USD Million (2017-2022)
  • Table 179. Mexico Aphakia, by Type USD Million (2017-2022)
  • Table 180. Mexico Aphakia, by Treatment USD Million (2017-2022)
  • Table 181. Mexico Aphakia, by Intraocular Lens Material USD Million (2017-2022)
  • Table 182. Mexico Aphakia, by Cause of Aphakia USD Million (2017-2022)
  • Table 183. Mexico Aphakia, by End User USD Million (2017-2022)
  • Table 184. Mexico Aphakia, by Symptoms USD Million (2017-2022)
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Aphakia: by Type(USD Million)
  • Table 196. Aphakia Primary , by Region USD Million (2023-2028)
  • Table 197. Aphakia Secondary , by Region USD Million (2023-2028)
  • Table 198. Aphakia: by Treatment(USD Million)
  • Table 199. Aphakia Spectacles , by Region USD Million (2023-2028)
  • Table 200. Aphakia Contact Lenses , by Region USD Million (2023-2028)
  • Table 201. Aphakia Intraocular Lens Implantation , by Region USD Million (2023-2028)
  • Table 202. Aphakia Refractive Surgery , by Region USD Million (2023-2028)
  • Table 203. Aphakia: by Intraocular Lens Material(USD Million)
  • Table 204. Aphakia PMMA , by Region USD Million (2023-2028)
  • Table 205. Aphakia Silicon , by Region USD Million (2023-2028)
  • Table 206. Aphakia Hydrogel , by Region USD Million (2023-2028)
  • Table 207. Aphakia: by Cause of Aphakia(USD Million)
  • Table 208. Aphakia Cataracts , by Region USD Million (2023-2028)
  • Table 209. Aphakia Genetics , by Region USD Million (2023-2028)
  • Table 210. Aphakia Injuries , by Region USD Million (2023-2028)
  • Table 211. Aphakia: by End User(USD Million)
  • Table 212. Aphakia Hospitals , by Region USD Million (2023-2028)
  • Table 213. Aphakia Ophthalmic Clinics , by Region USD Million (2023-2028)
  • Table 214. Aphakia Others , by Region USD Million (2023-2028)
  • Table 215. Aphakia: by Symptoms(USD Million)
  • Table 216. Aphakia Defective vision , by Region USD Million (2023-2028)
  • Table 217. Aphakia Erythropsia and cyanopsia , by Region USD Million (2023-2028)
  • Table 218. South America Aphakia, by Country USD Million (2023-2028)
  • Table 219. South America Aphakia, by Type USD Million (2023-2028)
  • Table 220. South America Aphakia, by Treatment USD Million (2023-2028)
  • Table 221. South America Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 222. South America Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 223. South America Aphakia, by End User USD Million (2023-2028)
  • Table 224. South America Aphakia, by Symptoms USD Million (2023-2028)
  • Table 225. Brazil Aphakia, by Type USD Million (2023-2028)
  • Table 226. Brazil Aphakia, by Treatment USD Million (2023-2028)
  • Table 227. Brazil Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 228. Brazil Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 229. Brazil Aphakia, by End User USD Million (2023-2028)
  • Table 230. Brazil Aphakia, by Symptoms USD Million (2023-2028)
  • Table 231. Argentina Aphakia, by Type USD Million (2023-2028)
  • Table 232. Argentina Aphakia, by Treatment USD Million (2023-2028)
  • Table 233. Argentina Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 234. Argentina Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 235. Argentina Aphakia, by End User USD Million (2023-2028)
  • Table 236. Argentina Aphakia, by Symptoms USD Million (2023-2028)
  • Table 237. Rest of South America Aphakia, by Type USD Million (2023-2028)
  • Table 238. Rest of South America Aphakia, by Treatment USD Million (2023-2028)
  • Table 239. Rest of South America Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 240. Rest of South America Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 241. Rest of South America Aphakia, by End User USD Million (2023-2028)
  • Table 242. Rest of South America Aphakia, by Symptoms USD Million (2023-2028)
  • Table 243. Asia Pacific Aphakia, by Country USD Million (2023-2028)
  • Table 244. Asia Pacific Aphakia, by Type USD Million (2023-2028)
  • Table 245. Asia Pacific Aphakia, by Treatment USD Million (2023-2028)
  • Table 246. Asia Pacific Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 247. Asia Pacific Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 248. Asia Pacific Aphakia, by End User USD Million (2023-2028)
  • Table 249. Asia Pacific Aphakia, by Symptoms USD Million (2023-2028)
  • Table 250. China Aphakia, by Type USD Million (2023-2028)
  • Table 251. China Aphakia, by Treatment USD Million (2023-2028)
  • Table 252. China Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 253. China Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 254. China Aphakia, by End User USD Million (2023-2028)
  • Table 255. China Aphakia, by Symptoms USD Million (2023-2028)
  • Table 256. Japan Aphakia, by Type USD Million (2023-2028)
  • Table 257. Japan Aphakia, by Treatment USD Million (2023-2028)
  • Table 258. Japan Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 259. Japan Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 260. Japan Aphakia, by End User USD Million (2023-2028)
  • Table 261. Japan Aphakia, by Symptoms USD Million (2023-2028)
  • Table 262. India Aphakia, by Type USD Million (2023-2028)
  • Table 263. India Aphakia, by Treatment USD Million (2023-2028)
  • Table 264. India Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 265. India Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 266. India Aphakia, by End User USD Million (2023-2028)
  • Table 267. India Aphakia, by Symptoms USD Million (2023-2028)
  • Table 268. South Korea Aphakia, by Type USD Million (2023-2028)
  • Table 269. South Korea Aphakia, by Treatment USD Million (2023-2028)
  • Table 270. South Korea Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 271. South Korea Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 272. South Korea Aphakia, by End User USD Million (2023-2028)
  • Table 273. South Korea Aphakia, by Symptoms USD Million (2023-2028)
  • Table 274. Taiwan Aphakia, by Type USD Million (2023-2028)
  • Table 275. Taiwan Aphakia, by Treatment USD Million (2023-2028)
  • Table 276. Taiwan Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 277. Taiwan Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 278. Taiwan Aphakia, by End User USD Million (2023-2028)
  • Table 279. Taiwan Aphakia, by Symptoms USD Million (2023-2028)
  • Table 280. Australia Aphakia, by Type USD Million (2023-2028)
  • Table 281. Australia Aphakia, by Treatment USD Million (2023-2028)
  • Table 282. Australia Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 283. Australia Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 284. Australia Aphakia, by End User USD Million (2023-2028)
  • Table 285. Australia Aphakia, by Symptoms USD Million (2023-2028)
  • Table 286. Rest of Asia-Pacific Aphakia, by Type USD Million (2023-2028)
  • Table 287. Rest of Asia-Pacific Aphakia, by Treatment USD Million (2023-2028)
  • Table 288. Rest of Asia-Pacific Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 289. Rest of Asia-Pacific Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 290. Rest of Asia-Pacific Aphakia, by End User USD Million (2023-2028)
  • Table 291. Rest of Asia-Pacific Aphakia, by Symptoms USD Million (2023-2028)
  • Table 292. Europe Aphakia, by Country USD Million (2023-2028)
  • Table 293. Europe Aphakia, by Type USD Million (2023-2028)
  • Table 294. Europe Aphakia, by Treatment USD Million (2023-2028)
  • Table 295. Europe Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 296. Europe Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 297. Europe Aphakia, by End User USD Million (2023-2028)
  • Table 298. Europe Aphakia, by Symptoms USD Million (2023-2028)
  • Table 299. Germany Aphakia, by Type USD Million (2023-2028)
  • Table 300. Germany Aphakia, by Treatment USD Million (2023-2028)
  • Table 301. Germany Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 302. Germany Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 303. Germany Aphakia, by End User USD Million (2023-2028)
  • Table 304. Germany Aphakia, by Symptoms USD Million (2023-2028)
  • Table 305. France Aphakia, by Type USD Million (2023-2028)
  • Table 306. France Aphakia, by Treatment USD Million (2023-2028)
  • Table 307. France Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 308. France Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 309. France Aphakia, by End User USD Million (2023-2028)
  • Table 310. France Aphakia, by Symptoms USD Million (2023-2028)
  • Table 311. Italy Aphakia, by Type USD Million (2023-2028)
  • Table 312. Italy Aphakia, by Treatment USD Million (2023-2028)
  • Table 313. Italy Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 314. Italy Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 315. Italy Aphakia, by End User USD Million (2023-2028)
  • Table 316. Italy Aphakia, by Symptoms USD Million (2023-2028)
  • Table 317. United Kingdom Aphakia, by Type USD Million (2023-2028)
  • Table 318. United Kingdom Aphakia, by Treatment USD Million (2023-2028)
  • Table 319. United Kingdom Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 320. United Kingdom Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 321. United Kingdom Aphakia, by End User USD Million (2023-2028)
  • Table 322. United Kingdom Aphakia, by Symptoms USD Million (2023-2028)
  • Table 323. Netherlands Aphakia, by Type USD Million (2023-2028)
  • Table 324. Netherlands Aphakia, by Treatment USD Million (2023-2028)
  • Table 325. Netherlands Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 326. Netherlands Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 327. Netherlands Aphakia, by End User USD Million (2023-2028)
  • Table 328. Netherlands Aphakia, by Symptoms USD Million (2023-2028)
  • Table 329. Rest of Europe Aphakia, by Type USD Million (2023-2028)
  • Table 330. Rest of Europe Aphakia, by Treatment USD Million (2023-2028)
  • Table 331. Rest of Europe Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 332. Rest of Europe Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 333. Rest of Europe Aphakia, by End User USD Million (2023-2028)
  • Table 334. Rest of Europe Aphakia, by Symptoms USD Million (2023-2028)
  • Table 335. MEA Aphakia, by Country USD Million (2023-2028)
  • Table 336. MEA Aphakia, by Type USD Million (2023-2028)
  • Table 337. MEA Aphakia, by Treatment USD Million (2023-2028)
  • Table 338. MEA Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 339. MEA Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 340. MEA Aphakia, by End User USD Million (2023-2028)
  • Table 341. MEA Aphakia, by Symptoms USD Million (2023-2028)
  • Table 342. Middle East Aphakia, by Type USD Million (2023-2028)
  • Table 343. Middle East Aphakia, by Treatment USD Million (2023-2028)
  • Table 344. Middle East Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 345. Middle East Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 346. Middle East Aphakia, by End User USD Million (2023-2028)
  • Table 347. Middle East Aphakia, by Symptoms USD Million (2023-2028)
  • Table 348. Africa Aphakia, by Type USD Million (2023-2028)
  • Table 349. Africa Aphakia, by Treatment USD Million (2023-2028)
  • Table 350. Africa Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 351. Africa Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 352. Africa Aphakia, by End User USD Million (2023-2028)
  • Table 353. Africa Aphakia, by Symptoms USD Million (2023-2028)
  • Table 354. North America Aphakia, by Country USD Million (2023-2028)
  • Table 355. North America Aphakia, by Type USD Million (2023-2028)
  • Table 356. North America Aphakia, by Treatment USD Million (2023-2028)
  • Table 357. North America Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 358. North America Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 359. North America Aphakia, by End User USD Million (2023-2028)
  • Table 360. North America Aphakia, by Symptoms USD Million (2023-2028)
  • Table 361. United States Aphakia, by Type USD Million (2023-2028)
  • Table 362. United States Aphakia, by Treatment USD Million (2023-2028)
  • Table 363. United States Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 364. United States Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 365. United States Aphakia, by End User USD Million (2023-2028)
  • Table 366. United States Aphakia, by Symptoms USD Million (2023-2028)
  • Table 367. Canada Aphakia, by Type USD Million (2023-2028)
  • Table 368. Canada Aphakia, by Treatment USD Million (2023-2028)
  • Table 369. Canada Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 370. Canada Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 371. Canada Aphakia, by End User USD Million (2023-2028)
  • Table 372. Canada Aphakia, by Symptoms USD Million (2023-2028)
  • Table 373. Mexico Aphakia, by Type USD Million (2023-2028)
  • Table 374. Mexico Aphakia, by Treatment USD Million (2023-2028)
  • Table 375. Mexico Aphakia, by Intraocular Lens Material USD Million (2023-2028)
  • Table 376. Mexico Aphakia, by Cause of Aphakia USD Million (2023-2028)
  • Table 377. Mexico Aphakia, by End User USD Million (2023-2028)
  • Table 378. Mexico Aphakia, by Symptoms USD Million (2023-2028)
  • Table 379. Research Programs/Design for This Report
  • Table 380. Key Data Information from Secondary Sources
  • Table 381. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aphakia: by Type USD Million (2017-2022)
  • Figure 5. Global Aphakia: by Treatment USD Million (2017-2022)
  • Figure 6. Global Aphakia: by Intraocular Lens Material USD Million (2017-2022)
  • Figure 7. Global Aphakia: by Cause of Aphakia USD Million (2017-2022)
  • Figure 8. Global Aphakia: by End User USD Million (2017-2022)
  • Figure 9. Global Aphakia: by Symptoms USD Million (2017-2022)
  • Figure 10. South America Aphakia Share (%), by Country
  • Figure 11. Asia Pacific Aphakia Share (%), by Country
  • Figure 12. Europe Aphakia Share (%), by Country
  • Figure 13. MEA Aphakia Share (%), by Country
  • Figure 14. North America Aphakia Share (%), by Country
  • Figure 15. Global Aphakia share by Players 2022 (%)
  • Figure 16. Global Aphakia share by Players (Top 3) 2022(%)
  • Figure 17. Global Aphakia share by Players (Top 5) 2022(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Johnson&JohnsonServices,Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Johnson&JohnsonServices,Inc. (United States) Revenue: by Geography 2022
  • Figure 21. OphtecBV (Netherland) Revenue, Net Income and Gross profit
  • Figure 22. OphtecBV (Netherland) Revenue: by Geography 2022
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 25. Rayner (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Rayner (United Kingdom) Revenue: by Geography 2022
  • Figure 27. Bohus BioTech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 28. Bohus BioTech AB (Sweden) Revenue: by Geography 2022
  • Figure 29. Lifecore Biomedical (United States) Revenue, Net Income and Gross profit
  • Figure 30. Lifecore Biomedical (United States) Revenue: by Geography 2022
  • Figure 31. Aetna Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Aetna Inc. (United States) Revenue: by Geography 2022
  • Figure 33. The Cooper Companies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. The Cooper Companies Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Menicon (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Menicon (Japan) Revenue: by Geography 2022
  • Figure 37. Labtician Ophthalmics, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 38. Labtician Ophthalmics, Inc. (Canada) Revenue: by Geography 2022
  • Figure 39. Global Aphakia: by Type USD Million (2023-2028)
  • Figure 40. Global Aphakia: by Treatment USD Million (2023-2028)
  • Figure 41. Global Aphakia: by Intraocular Lens Material USD Million (2023-2028)
  • Figure 42. Global Aphakia: by Cause of Aphakia USD Million (2023-2028)
  • Figure 43. Global Aphakia: by End User USD Million (2023-2028)
  • Figure 44. Global Aphakia: by Symptoms USD Million (2023-2028)
  • Figure 45. South America Aphakia Share (%), by Country
  • Figure 46. Asia Pacific Aphakia Share (%), by Country
  • Figure 47. Europe Aphakia Share (%), by Country
  • Figure 48. MEA Aphakia Share (%), by Country
  • Figure 49. North America Aphakia Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Johnson&JohnsonServices,Inc. (United States)
  • OphtecBV (Netherland)
  • Novartis (Switzerland)
  • Rayner (United Kingdom)
  • Bohus BioTech AB (Sweden)
  • Lifecore Biomedical (United States)
  • Aetna Inc. (United States)
  • The Cooper Companies Inc. (United States)
  • Menicon (Japan)
  • Labtician Ophthalmics, Inc. (Canada)
Additional players considered in the study are as follows:
Contact Fill (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 166 Pages 58 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Aphakia Market Quantitative research analysis
Global Aphakia Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Aphakia market are Johnson&JohnsonServices,Inc. (United States), OphtecBV (Netherland), Novartis (Switzerland), Rayner (United Kingdom), Bohus BioTech AB (Sweden), Lifecore Biomedical (United States), Aetna Inc. (United States), The Cooper Companies Inc. (United States), Menicon (Japan) and Labtician Ophthalmics, Inc. (Canada), to name a few.
is dominating the Aphakia Market.
"Poor cosmetic appearance " is seen as one of the major challenges by many Industry Players of Aphakia Market
The Aphakia market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Aphakia market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Aphakia Market Report?

Have a Query? Click Here

Other Related Reports

Physical Examination Comprehensive Study by Type (Routine Physical Examination, Comprehensive Physical Examination, Others), Application (Enterprises, Individuals), End Use (Hospitals, Clinics, Other...
$ 3500
Myelofibrosis Comprehensive Study by Type (Gene Mutation Analysis, Bone Marrow Biopsy, Imaging Tests, Blood Tests), Treatement (Chemotherapy, Blood Transfusions, Stem Cell Transplant, Splenectomy, Ra...
$ 3450
Adenoid Cystic Carcinom Comprehensive Study by By Test Type (Magnetic resonance imaging, Computerized tomography, Positron emission tomography), Grade type (Tubular, Cribriform, Solid), Age Group (Ch...
$ 3450
Healthcare Contract Research Organization Comprehensive Study by Type (Early Phase development, Clinical research, Laboratory regulatory Consulting), Therapeutic Areas (Oncology, CNS Disorder, Cardio...
$ 3750
Human Papillomavirus Testing Comprehensive Study by Type (Primary Testing, Follow-up Testing, Co-Testing), Application (Immunoassays, Monoclonal and Polyclonal Antibodies, Microarrays, Molecular Diag...
$ 3650
Paramedic Services Comprehensive Study by Type (Emergency Paramedic Services, General Paramedic Services), Application (Pre-hospital Support, Post-hospital Support), Service Level (Basic Life Support...
$ 3750